Skip to Content

Pond Pills

Protein-based drugs are big business, worth more than $17 billion a year. Genetically engineered bacteria and yeast efficiently churn out many protein pharmaceuticals, but as the proteins get more complex, the simple microbes sometimes fail. Drugmakers must then turn to increasingly expensive systems to make the proteins, which drives prices through the roof. Pittsboro, NC-based Biolex may have found an alternative: genetically engineer duckweed, a flowering pond plant, to secrete human proteins. The tiny plants grow very rapidly in a simple nutrient solution-doubling in population every 36 hours-and contain exceptionally large amounts of proteins. Biolex has proved the plants can do the work by using them to make complex therapeutic proteins such as interferons, which are used to treat some forms of cancer and hepatitis. The company is tweaking the system to increase efficiency and says that duckweed-produced drugs could be ready for testing in two to four years.

Keep Reading

Most Popular

A Roomba recorded a woman on the toilet. How did screenshots end up on Facebook?

Robot vacuum companies say your images are safe, but a sprawling global supply chain for data from our devices creates risk.

A startup says it’s begun releasing particles into the atmosphere, in an effort to tweak the climate

Make Sunsets is already attempting to earn revenue for geoengineering, a move likely to provoke widespread criticism.

10 Breakthrough Technologies 2023

Every year, we pick the 10 technologies that matter the most right now. We look for advances that will have a big impact on our lives and break down why they matter.

The viral AI avatar app Lensa undressed me—without my consent

My avatars were cartoonishly pornified, while my male colleagues got to be astronauts, explorers, and inventors.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.